Neoprobe’s Phase III Lymphoseek Study Reaches Accrual Goal

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study’s primary accrual objective.
FreshNews.com